Clinical trial Recruiting at 1 site Observational Ages 18 to 40

Finding and confirming saliva biomarkers for early periodontitis

Official title: Discovery and Validation of Periodontitis Biomarkers

Run by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · NCT07293481 · Data updated 2026-11-12

This project tests whether saliva-based biomarkers combined with an AI app can detect early periodontitis in adults aged 18–40.

More Periodontitis trials

Quick facts

Study typeObservational
Ages18 Years to 40 Years
SexAll
Enrollment228 (estimated)
SponsorShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedJuly 21, 2025
Main results expectedMarch 31, 2027
Study endsOctober 31, 2027
Registry record updatedApril 20, 2026
Trial IDNCT07293481 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–40 with gingivitis or stage I periodontitis who can provide informed consent and comply with study procedures are ideal candidates.

Probably not a fit

People who are pregnant or breastfeeding, recently treated with antibiotics or periodontal therapy, have salivary gland or mucosal diseases, severe systemic illness, or advanced periodontitis are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational diagnostic study will enroll adults with gingivitis or stage I periodontitis and collect saliva samples and clinical data at Shanghai Ninth People's Hospital. Researchers will use molecular and/or biomarker analysis of saliva alongside a patented AI-based self-detection app to identify candidate markers linked to early disease. The study aims to validate which saliva signals reliably indicate early periodontitis and compare AI predictions with clinical periodontal exams. Findings will inform whether the saliva test and app could be used for population-level screening or risk identification.

Why it matters

Potential benefit: If successful, the work could enable easier, noninvasive, earlier detection of periodontitis via a saliva test and AI app, helping to prevent disease progression.

How similar studies have gone: Previous research has shown promise for saliva biomarkers and AI-based detection of periodontal disease, but large-scale validation for population screening remains limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Adults between 18 and 40 years of age;
2. Diagnosed with varying degrees of periodontal disease, including gingivitis and stage I periodontitis;
3. Voluntarily agree to participate in the study, have signed the informed consent form, and are able to comply with the study protocol.

Exclusion Criteria:

1. Pregnant or breastfeeding women;
2. Individuals who have received antibiotic treatment within the past 3 months;
3. Individuals who have received periodontal treatment (including supragingival scaling) within the past 6 months;
4. Individuals with mucosal or salivary gland diseases (e.g., Sjögren's syndrome);
5. Individuals with severe systemic diseases, immune dysfunction, or health conditions that contraindicate surgery;
6. Individuals who are unwilling to cooperate with the study.

Where it's running

  • Shanghai 9th people's hospital
    Shanghai, Shanghai Municipality, China
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.